AMINO ACID MUTATIONS IN PLASMODIUM VIVAX DHFR AND DHPS FROM SEVERAL GEOGRAPHICAL REGIONS AND SUSCEPTIBILITY TO ANTIFOLATE DRUGS

ALYSON AULIFF, DANNY W. WILSON, BRUCE RUSSELL, QI GAO, NANHUA CHEN, LE NGOC ANH, JASON MAGUIRE, DAVID BELL, MICHAEL T. O'NEIL, AND QIN CHENG*
Department of Drug Resistance and Diagnostics, Australian Army Malaria Institute, Brisbane, Australia; Queensland Institute of Medical Research, Brisbane, Australia; Jiangsu Institute for Parasitic Diseases, Wuxi, China; Military Institute of Hygiene and Epidemiology, Department of Military Medicine, Vietnam; U.S. Naval Medical Research Unit 2, Jakarta, Indonesia; Division of Experimental Therapeutics, Walter Reed Army Institute of Research, Silver Springs, Maryland

Abstract. The increasing use of sulfadoxine-pyrimethamine (SP) for the treatment of chloroquine-resistant Plasmodium falciparum has resulted in increased reports of SP resistance of P. falciparum worldwide. Selection of SP-resistant Plasmodium vivax in areas where P. falciparum and P. vivax co-exist is not entirely clear. We examined the prevalence and extent of point mutations in pvdhfr and pvdhps in 70 P. vivax isolates from China, East Timor, Papua New Guinea (PNG), Philippines, Vanuatu, and Vietnam. Mutations in seven codon positions were found in pvdhfr, with the majority of isolates having double mutations (S58R/S117N). The greatest range of mutations was observed in the PNG and Vanuatu isolates, ranging from single to quadruple mutations (F57L/S58R/T61M/S117T). Single mutations in pvdhps were observed only in parasites with mutations in corresponding pvdhfr. Parasites with the S58R/S117N dhfr allelic type showed a MIC level for pyrimethamine and cycloguanil comparable to that previously reported, but were susceptible to WR99210.

INTRODUCTION

Of the four species of Plasmodium causing malaria in humans, Plasmodium vivax is most widely distributed and accounts for up to 80 million clinical cases annually. Although it causes very little mortality compared with Plasmodium falciparum, P. vivax is responsible for considerable morbidity and economic loss in endemic countries. Antifolate-sulfa antimalarial combinations such as sulfadoxine-pyrimethamine (SP) are not generally recommended for the treatment of P. vivax infections because the combination was reported to be less effective against the parasite. In practice, however, in areas where P. falciparum and P. vivax malaria infections co-exist, SP is given for any diagnosis of malarial fever. Thus the increasing use of SP for the treatment of chloroquine-resistant P. falciparum malaria exerts a strong selection for SP-resistant P. vivax.

SP is a combination of pyrimethamine (PYR) and sulfadoxine (SDX). Pyrimethamine targets dihydroreductase (dhfr), and SDX inhibits parasite dihydropteroate synthase (dhps). Point mutations in parasite dhfr and dhps genes confer resistance to PYR and SDX in P. falciparum. High-level resistance to PYR in P. falciparum results from the accumulation of mutations in pfdhfr, principally at codons 16, 51, 59, 108, and 164 (see review by Sibley). These mutations have been shown to alter the PYR-binding sites in pfdhfr and reduce enzyme–drug interactions. Parasites with >3 mutations in pfdhfr have been associated with SP treatment failures. Mutations have also been identified in P. vivax dhfr (pvdhfr) at positions 51, 58, and 117 corresponding to mutations at amino acids 50, 59, and 108 in P. falciparum, and the existence of such mutants correlates geographically with antifolate use against P. falciparum. Because it is difficult to maintain P. vivax in vitro cultures, Escherichia coli- and yeast-expressed pvdhfrs have been used to demonstrate that mutations in the pvdhfr correlate with reductions in susceptibility to PYR. Recently, novel mutations in pfdhfr, L57R and T61M, have been reported in combination with S58R/S117T in isolates from West Papua, Indonesia.

Genetic mutations at positions 436, 437, 540, 581, and 613 in dhps have been found to result in SDX resistance in P. falciparum. Like P. falciparum, mutations were also identified in P. vivax dhps (pvdhps) at positions 383 and 553, corresponding to mutations of 437 and 581 in pfdhps. The amino acid (V585) at the predicted drug-binding site in pvdhps was predicted to affect the binding of SDX to pvdhps and thus be responsible for innate resistance to sulfadoxine. Examination of pvdhps sequences from larger numbers of isolates collected from geographically different regions would provide support for this prediction.

In P. falciparum parasites, development of resistant mutations in pfdhfr and pfdhps is asymmetric (reviewed by Sibley). In the field, mutations in pfdhfr appear to be selected prior to those in pfdhps. It is unclear whether a similar selection process also occurs in P. vivax because the sequence of pvdhps has become available only recently and there is no information on mutations in pvdhfr and pvdhps in a single set of parasites.

The increasing failure rate of SP for treatment of uncomplicated P. falciparum malaria in many areas has led to the development of new combinations of sulfas and dihydrofolate inhibitors such as LapDap and homologues of WR99210. Although these drugs have been shown to be more potent than SP against P. falciparum with mild resistance to SP, their efficacy in controlling P. vivax is not clear. Because it is inevitable that P. vivax patients will be exposed to antimalarial drugs that are designed for the treatment of P. falciparum in areas where both species co-exist, it would be desirable for the next generation of antifolate drugs to also be effective in treating P. vivax infections. A recent report of

* Address correspondence to Qin Cheng, Department of Drug Resistance and Diagnostics, Australian Army Malaria Institute, Weary Dunlop Drive, Gallipoli Barracks, Enoggera, Brisbane, Qld 4051, Australia. E-mail: qin.cheng@defence.gov.au
yeast-expressed pvdhfr with quadruple mutations having reduced susceptibility to WR99210 is of particular concern. Molecular surveys will provide the prevalence and distribution of various pvdhfr and pvdhps allelic types and help to predict the efficacy of LapDap or WR99210 in these regions.

To date, mutations in pvdhfr have been examined in parasites from only a very small number of P. vivax-endemic countries, namely, India, Indonesia, PNG, and Thailand. In this paper, we report mutations in both pvdhfr and pvdhps in P. vivax populations from China, East Timor, PNG, the Philippines, Vanuatu, and Vietnam.

MATERIALS AND METHODS

P. vivax-infected blood samples. Blood samples were collected from patients who acquired P. vivax infections in Agusan Del Sur, Mindanao, the Philippines (N = 15) in 2002 and in Fujian and Jiangsu provinces, China (N = 7) in 1994. The East Timor (N = 18) and PNG (N = 5) samples were collected from malaria patients reporting to the Australian Defence Force health facilities in East Timor during 2001 and in PNG during 1998. The Malo Island, Vanuatu (N = 18), samples were collected from malaria patients reporting to the U.S. Naval Medical Research Unit 2 (NAMRU-2) field site in 2005, and the Vietnam samples (N = 7) were collected from Truong Xuan Commune-Quang Binh Province in 2002. Collection of samples in the Philippines, East Timor, Vanuatu, PNG, and Vietnam and use of samples at AMI were approved by the Queensland Institute of Medical Research Human Research Ethics Committee; Division of Health Services, East Timor; Ministry of Health, Government of the Republic of Vanuatu; and Australian Defence Health Research Ethics Committee, respectively. For individuals whose samples underwent in vitro susceptibility testing, a treatment history was taken. Individuals who had taken any anti-malarial drugs over the previous 7 days were excluded from in vitro testing.

DNA isolation. Blood samples were stored on filter papers or in 6 M guanidine-HCl solution. Genomic DNA was isolated from the samples using previously described methods.

Confirmation of Plasmodium species. A multiplex PCR using conditions previously described by Padley was performed to confirm the presence of Plasmodium species in all isolates collected.

Amplification of pvdhfr and pvdhps. pvdhfr was amplified with primers pvdhfr1 (5’ ATGGAGGACCTTTCAGTAGTATT 3’) and pvdhfr2 (5’ CCACCTTGCTGTAAACTG-CAAAAAGTCCAGAG 3’) using conditions described earlier. The amplified fragment corresponds to amino acids 30–225. pvdhps was amplified using primers and conditions described previously.

Sequence analysis. DNA sequences were translated into amino acid sequences and were then compared using the GCG program PILEUP (Wisconsin Package v. 8; Genetics Computer Group, Madison, WI) on the Australian National Genomic Information Service (ANGIS).

Field in vitro drug-susceptibility tests. P. vivax in vitro drug-susceptibility tests were performed using a modified microtest method developed by Rickemann and others. Briefly, plates were coated with PYR (Hoffmann-La Roche, Basel, Switzerland), CYC (ICI Pharmaceuticals, Macclesfield, Cheshire, United Kingdom), or WR99210 (Jacobus Pharmaceuticals, Princeton, NJ) and then standarized using in vitro-cultured chloroquine and PYR-resistant and PYR-sensitive P. falciparum strains K1 and FC27, respectively. An aliquot of 50 µL blood-RPMI 1640 (consisting of 0.0005 mg/L para-aminobenzoic acid, 0.01 mg/L folate, L-glutamine) medium mixture (4% hematocrit) was added to each well and incubated in a culture chamber containing 5% CO2, 5% O2, and 95% N2 at 37°C, until ~50% of the ring-stage parasites had matured to schizonts (24–36 hours). Contents of the wells were transferred onto microscope slides, stained with Giemsa, and examined via microscopy. The MIC of each drug (the minimum concentration at which ~99% of the parasites, relative to the control, were inhibited from developing to schizonts, which are parasites with one or more chromatin dots) was determined for each isolate. Degenerate schizonts (normal appearance except that the chromatin dot appeared smudged and out of shape) were not counted.

RESULTS

pvdhfr alleles and their prevalence. All isolates were confirmed as P. vivax by only multiplex PCR (data not shown). Amino acid comparison of pvdhfr from 70 samples originating from 6 countries revealed changes at several amino acid positions. These changes and corresponding positions of mutations observed in pvdhfr are shown in Table 1. Various numbers of wild-type alleles were identified from parasites originating from all countries, with frequencies ranging from 5.6% in Vanuatu to 71.4% in China (Table 1). Overall, the proportion of wild-type pvdhfr was identified in 26% of the samples (18/70); the remaining 74% of isolates carried a mutant pvdhfr. The mutant pvdhfr isolates from China, East Timor, Philippines, Vanuatu, and Vietnam had either a single mutation of S117N or S58R or a combination of two mutations: S58R/S117N. This double-mutant allele plus F57L/S117N and F57L/S58R/S117N were observed in PNG isolates. Alleles with triple mutations S58R/T61M/S117T and F57L/S117T/I173F were identified in isolates from Vanuatu. Quadruple mutant alleles of F57L/S58R/T61M/S117T and S58R/T61M/S117T/I173F were identified in isolates from PNG and Vanuatu, respectively. Among all countries examined, isolates from Vanuatu had the highest frequency (95%) and greatest range of mutant pvdhfr alleles (single, double, triple, and quadruple mutations).

Variation in repeats in pvdhfr. Different numbers of an 18-bp repeat (6 amino acids) were observed in the pvdhfr gene between amino acid positions 92 and 118, which is consistent with previous reports. The majority of the isolates sequenced (86%) contained two 18-bp repeats. A small number of isolates (13%) contained one 18-bp repeat. One isolate from PNG was found to have three 18-bp repeats.

Mutation frequencies in pvdhps. pvdhps was sequenced and analyzed from 37 of the 70 P. vivax isolates from the 6 geographically diverse regions mentioned above (Table 1). An amino acid sequence comparison revealed only two amino acid changes among the P. vivax isolates: A383G in two isolates from the Philippines and in four isolates from Vietnam and A553G in one PNG isolate. The remaining sequences were wild-type (81% (30/37)). The amino acid at position 585 in all of the P. vivax dhp5 sequences contained a Val compared with an Ala in wild-type P. falciparum dhp5 sequences. All isolates that had mutations in pvdhps were
also found to have mutations in corresponding *pvdhfr*, and 87% (26/30) of isolates with wild-type *pvdhps* were found to have mutations in the corresponding *pvdhfr* (Table 1).

**In vitro drug susceptibility.** Four of the nine *P. vivax* isolates from East Timor that were sequenced were tested for their susceptibilities to PYR, CYC, and WR99210. Three isolates had double mutations of S58R/S117N, and one isolate had a single mutation of S117N in *pvdhfr*. The MIC values to PYR and CYC for all four isolates tested were greater than 5.0 and 2.0 pmol/well, respectively. The isolates were all susceptible to WR99210 at 0.025 pmol/well.

**DISCUSSION**

Genetic mutations in *pfdhfr* and *pfdhps* and their correlations with PYR and SDX resistance in *vivo* and *in vitro* have been widely reported from many locations in various countries and regions (see review by Sibley). As a result, the prevalence and extent of antifolate resistance in *P. falciparum* populations is comprehensive. In comparison, the prevalence and extent of antifolate resistance in *P. vivax* has been much less investigated.

In this study, we examined genetic mutations in *dhfr* and *dhps* in *P. vivax* samples from six Asian-Pacific countries and showed that PYR-resistant mutations were present in samples collected from each country, with parasites from the South West Pacific countries of PNG and Vanuatu carrying the highly resistant *dhfr* allelic types with triple or quadruple mutations. The prevalence and distribution of the resistant allelic types in these two countries are similar to those reported earlier from PNG, Indonesia, and Thailand. In contrast, *P. vivax* parasites from China, East Timor, the Philippines, and Vietnam were found to carry, at most, double *dhfr* mutations similar to those reported for samples from South America and Africa. The wild-type *dhfr* allele is present at a relatively high proportion in *P. vivax* parasites from these countries. The difference in the prevalence of mutant *pvdhfr* alleles reflects the selection pressure exerted by the antifolate drug in these countries.

Of the 70 isolates screened for *pvdhfr* mutations, 52 were identified as having a mutant *pvdhfr* allele, of which 30 isolates (58%) had double mutations of S58R/S117N. The high prevalence of double mutations compared with other mutant alleles suggests that the combination of S58R/S117N may be the result of primary drug selection toward the development of resistance to SP. *pvdhfr* alleles with greater than triple mutations were observed in tandem with only S117T, not S117N, suggesting S117T is a key mutation in the development of high resistance to antifolate drugs, consistent with previous findings. Although a significant number of *P. vivax* isolates were identified to carry double mutations in their *dhfr*, it is unlikely that these parasites will fail SP treatment because failure with SP is only significantly associ-
ated with isolates having a quadruple mutant pvdhfr allele.\textsuperscript{14,15}

The \textit{in vitro} drug-susceptibility assay demonstrated that the parasites carrying the double-mutant pvdhfr allele had MIC values for PYR and CYC at \(> 5 \text{ pmol/well (100 N M)}\), comparable to those (\(\approx 150 \text{ nM}\)) reported by de Pecoulas et al. for \(P. \) vivax isolates carrying identical double mutations.\textsuperscript{11} However, it is not yet clear how these MIC values will compare with the \(P. \) vivax parasites that have wild-type \(dhfr\). Our \textit{in vitro} cultures performed in the field prior to determination of the parasite \(dhfr\) mutant status by PCR and sequencing; it was unfortunate that all of the parasites that we tested in the field happened to have mutant \(dhfr\). Further studies are required to determine the susceptibility of \(P. \) vivax isolates with wild-type \(pvdhfr\) to antifolates. \textit{In vitro} drug-susceptibility testing has also shown that isolates from East Timor carrying double or single mutations in \(pvdhfr\) were highly susceptible to WR99210. This is consistent with results from experiments conducted in a yeast system\textsuperscript{17} showing that WR99210 is an extremely effective inhibitor of the \(pvdhfr\). However, whether \(P. \) vivax with quadruple-mutant \(dhfr\) is still susceptible to WR99210 requires further investigation.

A small number of mutations were detected in \(pvdhps\). Of the \(pvdhps\) gene from 37 \(P. \) vivax isolates from the 6 countries, only 7 were found to carry a single mutation of A383G or A553G, corresponding to A347G and A581G in \(P. \) falciparum, respectively. A great majority (87\%) of \(pvdhps\) wild-type parasites had mutations in corresponding \(pvdhfr\), and all \(pvdhfr\) mutant parasites also had mutations in corresponding \(pvdhfr\), supporting the conclusion that the asymmetric selection process observed in \(P. \) falciparum also occurs in \(P. \) vivax. Note that all of the \(pvdhps\) that were examined had V585, providing further support to our prediction that this amino acid is associated with innate resistance to SDX in \(P. \) vivax. Addition of mutations to \(pvdhps\) may enhance innate resistance to SDX and confer resistance to other sulfa drugs.

In conclusion, our data demonstrate that \(P. \) vivax-carrying mutant \(dhfr\) allelic types are present in all six Asian-Pacific countries examined in this study, with the highly resistant mutant allelic types being more prevalent in Western Pacific countries. Because chloroquine-resistant \(P. \) vivax is also prevalent in the region,\textsuperscript{26–30} the need to develop alternative drugs and strategies for effectively treating \(P. \) vivax infections is urgent.

Received February 23, 2006. Accepted for publication June 12, 2006.

Acknowledgments: \(P. \) vivax isolates from Agusan Dal Sar, Mindanao, Philippines, were collected as part of a project funded by the National Health and Medical Research Council, Australia, and assisted by AusAID through the Research Institute for Tropical Medicine, Philippines. We thank colleagues from the Malaria Study Group, Research Institute for Tropical Medicine, for collecting malaria-infected samples in the Philippines. \(P. \) vivax isolates from Vietnam were obtained as part of a Vietnam Australia Defence Malaria Project (VADMP), co-operative project between the Vietnam People’s Army and the Australian Defence Force. The VADMP is sponsored by the International Policy Division, Department of Defence, Australia.

Disclaimer: The opinions expressed herein are those of the authors and do not necessarily reflect those of the Defence Health Service or any extant policy of Department of Defence, Australia, or United States Army.

The DNA sequences of \(pvdhfr\) and \(pvdhps\) have been deposited in the GenBank database (accession numbers DQ244102–DQ244124 and DQ379957–DQ379962, respectively).

Authors’ addresses: Alyson M. Auliff, Nanhua Chen, Mike O’Neil, and Qin Cheng, Department of Drug Resistance and Diagnostics, Australian Army Malaria Institute, Weary Dunlop Drive, Gallipoli Barracks, Enoggera, Brisbane, QLD 4051, Australia, Telephone: +61-7-3332 4801, Fax: +61-7-3332 4800, E-mails: alyson.auliff@defence.gov.au, nanhua.chen@defence.gov.au, mike.oneil@defence.gov.au, and qin.cheng@defence.gov.au. Danny Wilson, Walter and Eliza Hall Institute of Medical Research, Parkville, Melbourne, Vic, Australia, E-mail: dwilson@wehi.edu.au. Bruce Russell, International Health Research, Menzies School of Health Research, Casuarina NT, Australia, Telephone: +61-8-8922 7918, E-mail: Bruce.Russell@menzies.edu.au. Qi Gao, Jiangsu Institute of Parasitic Diseases, Wuxi, China, E-mail: gaqiq54@hotmail.com. Le Ngoc Anh, Military Institute of Hygiene and Epidemiology, Department of Military Medicine, Vietnam, E-mail: Le_Anh2001@yahoo.com.au. Jason Maguire, Infectious Disease Division, Naval Medical Center, Portsmouth, VA, E-mail: maguirejas@yahoo.com. David Bell, Western Pacific Regional Office, World Health Organization, Manila, Philippines, E-mail: belld@wpro.who.int.

REFERENCES


